Setting up a department of molecular pathology in oncology in a pathology laboratory (LPCE, CHU de Nice);Mise en place d'un secteur de pathologie moléculaire en oncologie au sein d'un laboratoire d'anatomie pathologique (LPCE, CHU de Nice)

Annales de Pathologie

Volumn 33, Issue 1, 2013, Pages 24-37

  Long, Elodie ^a   Hofman, Véronique ^a   Ilie, Marius ^a   Lespinet, Virgine ^a   Bonnetaud, Christelle ^a   Bordone, Olivier ^a   Gavric Tanga, Virginie ^a   Washetine, Kevin ^a   Gaziello, Marie Clotilde ^a   Mauro, Virginie ^a   Lassalle, Sandra ^a   Selva, Eric ^a   Zahaf, Katia ^a   Santini, José ^b   Castillo, Laurent ^b   Lacour, Jean Philippe ^c   Vénissac, Nicolas ^a   Mouroux, Jérôme ^a   Otto, Josiane ^d   Poudenx, Michel ^a   Marquette, Charles Hugo ^a   Sabourin, Jean Christophe ^e   Hofman, Paul ^a   more..

^a PASTEUR HOSPITAL   (France)

^b Institut universitaire de la face et du cou   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d Unité de pneumologie   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Accreditation; ISO 15189; Molecular biology; Molecular pathology; Quality assurance; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

ARTICLE; BUDGET; CANCER CENTER; CLINICAL TRIAL (TOPIC); COLON ADENOCARCINOMA; FRANCE; GENE MUTATION; GENETIC DISORDER; HOSPITAL DEPARTMENT; HUMAN; LABORATORY; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; ONCOLOGY WARD; PERSONALIZED MEDICINE; PHYSICIAN; QUALITY CONTROL; THYROID CANCER;

FRANCE; HUMANS; LABORATORIES; MEDICAL ONCOLOGY; PATHOLOGY, MOLECULAR; PRACTICE GUIDELINES AS TOPIC; RECORDS AS TOPIC;

EID: 84875244178     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2012.12.003     Document Type: Article

References (45)

1. Scott M.G., Smith B.R., Young I.S., WU A., Plebani M., Chiu R. How well are we training the next generation of clinical pathologists and clinical laboratory directors? A global perspective. Clin Chem 2012, 58:91-95.
2. Cheng L., Alexander R.E., Maclennan G.T., et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012, 25:347-369.
3. Diaz-Cano S.J. General morphological and biological features of neoplasms: integration of molecular findings. Histopathology 2008, 53:1-19.
4. Dietel M., Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. a review. Virchows Arch 2006, 448:744-755.
5. Dry S., Grody W.W., Papagni P. Stuck between a scalpel and a rock, or molecular pathology and legal-ethical issues in use of tissues for clinical care and research: what must a pathologist know?. Am J Clin Pathol 2012, 137:346-355.
6. Hofman V., Ilie M., Gavric-Tanga V., et al. Rôle du laboratoire d'anatomie-pathologique dans l'approche pré-analytique des examens de biologie moléculaire réalisés en pathologie tumorale. Ann Pathol 2010, 30:85-93.
7. Jones D., Fletcher C.D. How shall we apply the new biology to diagnostics in surgical pathology?. J Pathol 1999, 187:147-154.
8. Kulesza P., Ramchandran K., Patel J.D. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol 2011, 136:228-238.
9. Ladanyi M., Hogendoorn P.C. Cancer biology and genomics: translating discoveries, transforming pathology. J Pathol 2011, 223:99-101.
10. Moch H., Blank P.R., Dietel M., et al. Personalized cancer medicine and the future of pathology. Virchows Arch 2012, 460:3-8.
11. Tomlinson I.P., Ilyas M. Molecular pathology of solid tumours: some practical suggestions for translating research into clinical practice. Mol Pathol 2001, 54:203-205.
12. Norme NF ISO 15189. Laboratoires d'analyses de biologie médicale. Exigences particulières concernant la qualité et la compétence 2007, AFNOR.
13. Ilie M., Hofman P. Pitfalls in lung cancer molecular pathology: how to limit them in routine practice?. Curr Med Chem 2012, 19:2638-2651.
14. Ogino S., Kawasaki T., Brahmandam M., et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005, 7:413-421.
15. De Mattos-Arruda L., Dienstmann R., Tabernero J. Development of molecular biomarkers in individualized treatment of colorectal cancer. Clin Colorect Cancer 2011, 10:279-289.
16. Eberhard D.A., Giaccone G., Johnson B.E. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008, 26:983-994.
17. Gately K., O'Flaherty J., Cappuzzo F., Pirker R., Kerr K., O'Byrne K. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol 2012, 65:1-7.
18. Harris P.J., Bible KC Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs 2011, 20:1357-1375.
19. Li J., Chen F., Cona M.M., Feng Y., Himmelreich U., Oyen R., et al. A review on various targeted anticancer therapies. Target Oncol 2012, 7:69-85.
20. Mok T.S. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011, 8:661-668.
21. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7:569-580.
22. Richman S.D., Seymour M.T., Chambers P., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or Irinotecan: results From the MRC FOCUS Trial. J Clin Oncol 2009, 27:5931-5937.
23. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
24. Woodman S.E., Lazar A.J., Aldape K.D., Davies M.A. New strategies in melanoma: molecular testing in advanced disease. Clin Cancer Res 2012, 18:1195-1200.
25. Wood W.G. The preanalytical phase - can the requirements of the DIN-EN-ISO 15189 be met practically for all laboratories? A view of the " German situation" . Clin Lab 2005, 51:665-671.
26. Lassalle S., Hofman V., Marius I., et al. Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives. Thyroid 2009, 19:1239-1248.
27. Bellon E., Ligtenberg M.J., Tejpar S., et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011, 16:467-478.
28. Brambilla E., Lantuejoul S. New classification of pulmonary cancer: application to small size biopsy sampling. Ann Pathol 2010, 5:60-63.
29. Yauch R.L., Settleman J. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Curr Opin Genet Dev 2012, 22:45-49.
30. Cronin M., Ross J.S. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011, 5:293-305.
31. Schweiger M.R., Kerick M., Timmermann B., et al. Genome-wide massively parallel sequencing of formaldehyde fixed-paraffin embedded (FFPE) tumor tissues for copy-number- and mutation-analysis. PLoS One 2009, 4:e5548.
32. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
33. Hofman P., Ilie M., Hofman V., et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012, 23:1738-1743.
34. Ilie M.I., Hofman V., Bonnetaud C., et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010, 457:483-495.
35. Simonetti S., Molina M.A., Queralt C., et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 2010, 8:135.
36. Yu J., Kane S., Wu J., et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 2009, 15:3023-3028.
37. Koperek O., Kornauth C., Capper D., et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012, 36:844-850.
38. Bogenrieder T., Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomark 2011, 9:267-286.
39. Brousset P., Delsol G. Emergence d'une spéciliaté médicale nouvelle: la pathologie. Med Sci 2011, 27:651-655.
40. Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med 2011, 135:622-629.
41. Jiang Y., Wang M. Personalized medicine in oncology: tailoring the right drug to the right patient. Biomark Med 2010, 4:523-533.
42. La Thangue N.B., Kerr D.J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011, 8:587-596.
43. Rodriguez-Canales J., Eberle F.C., Jaffe E.S., Emmert-Buck M.R. Why is it crucial to reintegrate pathology into cancer research?. Bioessays 2011, 33:490-498.
44. Hewitt R.E. Biobanking: the foundation of personalized medicine. Curr Opin Oncol 2011, 23:112-119.
45. Fournet J.C. Pathologie integrative, un important champ de développement de la pathologie clinique. Ann Pathol 2012, 32:79-90.